Laurent Monassier
Laurent Monassier has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Estelle Ayme-Dietrich
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire EA7296, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg, Université et Centre Hospitalier de Strasbourg, Strasbourg, France
11 shared publications - Guillaume Becker
Service Pharmacie, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France
5 shared publications - Roland Lawson
University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France
5 shared publications Gaëlle Aubertin-Kirch
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire EA7296, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg, Université et Centre Hospitalier de Strasbourg, Strasbourg, France
3 shared publicationsLahcen El Fertak
Institut clinique de la Souris, institut de génétique et de biologie moléculaire et cellulaire, université de Strasbourg, Illkirch, France
3 shared publications- Luc Maroteaux
Sorbonne University
3 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Elsevier in Toxicology
- Vol. 524, 154474
Nicotine alters alveolar-barrier integrity by blocking autophagy and occludin trafficking
- 22 April 2026
- Published by Elsevier in Toxicology
- Vol. 524, 154474
Open AccessNicotine alters alveolar-barrier integrity by blocking autophagy and occludin trafficking
- Open Access
- 17 November 2025
- Published by Wiley in Journal of Medical Primatology
- Vol. 54 (6) , e70041
A Cross‐Sectional Evaluation of Cardiovascular and Metabolic Functions During Aging and Pregnancy in the Cynomolgus Monkey
Background: Cardiovascular and hemodynamic status can both be modified by cardiovascular risk factors which themselves depend on housing conditions. Methods: Cynomolgus macaques maintained in large enclosures allowing them to perform physical exercise and social interactions were evaluated for cardiovascular and metabolic parameters in three age groups (2–4, 5–10, and 10–15). Results: Liver and kidney functions were stable but an important variability of the blood neutrophil count was noticed. In males, an increase in alkaline phosphatase was noted in young animals while lipid parameters were altered over time with increases in triglycerides and cholesterol. Some diastolic disorders were observed in older males. No electrocardiographic abnormalities were observed. Finally, we observed usual physiological changes due to gestation. Conclusions: Housing conditions closer to those in the wild provide an improved health status over non‐human primates that are housed in more crowded housing conditions.
- 17 November 2025
- Published by Wiley in Journal of Medical Primatology
- Vol. 54 (6) , e70041
Open AccessA Cross‐Sectional Evaluation of Cardiovascular and Metabolic Functions During Aging and Pregnancy in the Cynomolgus Monkey
Background: Cardiovascular and hemodynamic status can both be modified by cardiovascular risk factors which themselves depend on housing conditions. Methods: Cynomolgus macaques maintained in large enclosures allowing them to perform physical exercise and social interactions were evaluated for cardiovascular and metabolic parameters in three age groups (2–4, 5–10, and 10–15). Results: Liver and kidney functions were stable but an important variability of the blood neutrophil count was noticed. In males, an increase in alkaline phosphatase was noted in young animals while lipid parameters were altered over time with increases in triglycerides and cholesterol. Some diastolic disorders were observed in older males. No electrocardiographic abnormalities were observed. Finally, we observed usual physiological changes due to gestation. Conclusions: Housing conditions closer to those in the wild provide an improved health status over non‐human primates that are housed in more crowded housing conditions.
- 8 February 2023
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 174, 113650
Flavoured and nicotine-containing e-liquids impair homeostatic properties of an alveolar-capillary cell model
- 8 February 2023
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 174, 113650
Flavoured and nicotine-containing e-liquids impair homeostatic properties of an alveolar-capillary cell model
- Open Access
- 3 November 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (11) , 1856
Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?
Serotonin affects many functions in the body, both in the central nervous system (CNS) and the periphery. However, its effect on the blood–brain barrier (BBB) in separating these two worlds has been scarcely investigated. The aim of this work was to characterize the serotonin receptor 5-HT4 in the hCMEC/D3 cell line, in the rat and the human BBB. We also examined the effect of prucalopride, a 5-HT4 receptor agonist, on the permeability of the hCMEC/D3 in an in vitro model of BBB. We then confirmed our observations by in vivo experiments. In this work, we show that the 5-HT4 receptor is expressed by hCMEC/D3 cells and in the capillaries of rat and human brains. Prucalopride increases the BBB permeability by downregulating the expression of the tight junction protein, occludin. This effect is prevented by GR113808, a 5-HT4 receptor antagonist, and is mediated by the Src/ERK1/2 signaling pathway. The canonical G-protein-dependent pathway does not appear to be involved in this phenomenon. Finally, the administration of prucalopride increases the diffusion of Evans blue in the rat brain parenchyma, which is synonymous with BBB permeabilization. All these data indicate that the 5-HT4 receptor contributes to the regulation of BBB permeability.
- 3 November 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (11) , 1856
Open AccessBlood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?
Serotonin affects many functions in the body, both in the central nervous system (CNS) and the periphery. However, its effect on the blood–brain barrier (BBB) in separating these two worlds has been scarcely investigated. The aim of this work was to characterize the serotonin receptor 5-HT4 in the hCMEC/D3 cell line, in the rat and the human BBB. We also examined the effect of prucalopride, a 5-HT4 receptor agonist, on the permeability of the hCMEC/D3 in an in vitro model of BBB. We then confirmed our observations by in vivo experiments. In this work, we show that the 5-HT4 receptor is expressed by hCMEC/D3 cells and in the capillaries of rat and human brains. Prucalopride increases the BBB permeability by downregulating the expression of the tight junction protein, occludin. This effect is prevented by GR113808, a 5-HT4 receptor antagonist, and is mediated by the Src/ERK1/2 signaling pathway. The canonical G-protein-dependent pathway does not appear to be involved in this phenomenon. Finally, the administration of prucalopride increases the diffusion of Evans blue in the rat brain parenchyma, which is synonymous with BBB permeabilization. All these data indicate that the 5-HT4 receptor contributes to the regulation of BBB permeability.
- 2 November 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (11) , 1855-1858
Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review
Introduction Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degradation following ACE inhibition. Clinical studies on ACE inhibitors mainly focus on their efficacy. Few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema. Case description We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Angioedema subsided spontaneously after ramipril discontinuation and quinapril reintroduction. Discussion and conclusions Our clinical case suggests that despite similar pharmacodynamic properties, quinapril and ramipril do not have the same potential to generate angioedema. To explain this difference, we suggest a potentiation of the effect of bradykinin at the B2 receptor level by ramipril, which does not occur with quinapril. Consequently, angioedema may not always be a class effect of ACE inhibitors.
- 2 November 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (11) , 1855-1858
Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review
Introduction Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degradation following ACE inhibition. Clinical studies on ACE inhibitors mainly focus on their efficacy. Few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema. Case description We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Angioedema subsided spontaneously after ramipril discontinuation and quinapril reintroduction. Discussion and conclusions Our clinical case suggests that despite similar pharmacodynamic properties, quinapril and ramipril do not have the same potential to generate angioedema. To explain this difference, we suggest a potentiation of the effect of bradykinin at the B2 receptor level by ramipril, which does not occur with quinapril. Consequently, angioedema may not always be a class effect of ACE inhibitors.
- Open Access
- 2 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257022
Characterization of the spontaneous degenerative mitral valve disease in FVB mice
Background: The development of new non-surgical treatments dedicated to mitral valve degeneration is limited by the absence of relevant spontaneous and rapidly progressing animal experimental models. Animals: We characterized the spontaneous mitral valve degeneration in two inbred FVB mouse strains compared to C57BL/6J and investigated a contribution of the serotonergic system. Methods: Males and females FVB/NJ and FVB/NRj were compared to the putative C57BL/6J control at 12, 16, 20 and 24 weeks of age. Body weight, systolic blood pressure, heart rate, urinary 5-hydroxyindoleacetic acid (5-HIAA), whole blood and plasma serotonin, tail bleeding time, blood cell count, plasma TGF-β1 and plasma natriuretic peptide concentrations were measured. Myocardium and mitral valves were characterized by histology. mRNA mitral expression of 5-HT2A and 5-HT2B receptors was measured in the anterior leaflet. Cardiac anatomy and function were assessed by echocardiography. Results: Compared to C57BL/6J, FVB mice strains did not significantly differ regarding body weight increase, arterial blood pressure and heart rate. A progressive augmentation of plasma pro-ANP was observed in FVB mice. Nevertheless, no cardiac hypertrophy or left-ventricular fibrosis were observed. Accordingly, plasma TGF-β1 was not different among the three strains. Conversely, FVB mice demonstrated a high prevalence of fibromyxoid highly cellularized and enriched in glycosaminoglycans lesions, inducing major mitral leaflets thickening without increase in length. The increased thickness was correlated with urinary 5-HIAA and blood platelet count. Whole blood serotonin concentration was similar in the two strains but, in FVB, a reduction of plasma serotonin was observed together with an increase of the bleeding time. Finally, echocardiography identified left atrial and left ventricular remodeling associated with thickening of both mitral leaflets and mitral insufficient in 30% of FVB mice but no systolic protrusion of mitral leaflets towards the atrium. Conclusion: The FVB mouse strain is highly prone to spontaneous mitral myxomatous degeneration. A contribution of the peripheral serotonergic system is suggested.
- 2 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257022
Open AccessCharacterization of the spontaneous degenerative mitral valve disease in FVB mice
Background: The development of new non-surgical treatments dedicated to mitral valve degeneration is limited by the absence of relevant spontaneous and rapidly progressing animal experimental models. Animals: We characterized the spontaneous mitral valve degeneration in two inbred FVB mouse strains compared to C57BL/6J and investigated a contribution of the serotonergic system. Methods: Males and females FVB/NJ and FVB/NRj were compared to the putative C57BL/6J control at 12, 16, 20 and 24 weeks of age. Body weight, systolic blood pressure, heart rate, urinary 5-hydroxyindoleacetic acid (5-HIAA), whole blood and plasma serotonin, tail bleeding time, blood cell count, plasma TGF-β1 and plasma natriuretic peptide concentrations were measured. Myocardium and mitral valves were characterized by histology. mRNA mitral expression of 5-HT2A and 5-HT2B receptors was measured in the anterior leaflet. Cardiac anatomy and function were assessed by echocardiography. Results: Compared to C57BL/6J, FVB mice strains did not significantly differ regarding body weight increase, arterial blood pressure and heart rate. A progressive augmentation of plasma pro-ANP was observed in FVB mice. Nevertheless, no cardiac hypertrophy or left-ventricular fibrosis were observed. Accordingly, plasma TGF-β1 was not different among the three strains. Conversely, FVB mice demonstrated a high prevalence of fibromyxoid highly cellularized and enriched in glycosaminoglycans lesions, inducing major mitral leaflets thickening without increase in length. The increased thickness was correlated with urinary 5-HIAA and blood platelet count. Whole blood serotonin concentration was similar in the two strains but, in FVB, a reduction of plasma serotonin was observed together with an increase of the bleeding time. Finally, echocardiography identified left atrial and left ventricular remodeling associated with thickening of both mitral leaflets and mitral insufficient in 30% of FVB mice but no systolic protrusion of mitral leaflets towards the atrium. Conclusion: The FVB mouse strain is highly prone to spontaneous mitral myxomatous degeneration. A contribution of the peripheral serotonergic system is suggested.
- 18 August 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 79 (2) , 229-234
Nischarin Is Not the Functional I1 Imidazoline Receptor Involved in Blood Pressure Regulation
Imidazoline receptor antisera selected/Nischarin was proposed several years ago as the functional entity for the I1 medullary receptors (I1Rs) targeted, together with α2-adrenoceptors, by the centrally acting antihypertensive drugs, such as clonidine. The objective of this study was to test this assumption using a pyrroline analog of clonidine, LNP599, which, unlike clonidine and related compounds, displays high selectivity toward I1Rs. Cardiovascular effects of LNP599 (3 mg/kg intravenous) were evaluated in anesthetized, artificially ventilated nischarin mutant rats expressing a truncated form of nischarin lacking the putative imidazoline binding site. LNP599 induced a rapid and pronounced fall in arterial blood pressure in wild-type animals (−42.7% ± 11.0% after 15 minutes), associated with a ≈30% heart rate reduction. Similar effects were obtained in homozygous and heterozygous nischarin mutant rats. The observation that the hypotensive response to I1R activation is not affected by the absence of the putative imidazoline binding site on nischarin strongly suggests that nischarin cannot be regarded as the functional I1R. Carbohydrate regulation was improved in nischarin mutant rats, further supporting the conclusion that nischarin and I1R are 2 distinct molecular entities.
- 18 August 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 79 (2) , 229-234
Nischarin Is Not the Functional I1 Imidazoline Receptor Involved in Blood Pressure Regulation
Imidazoline receptor antisera selected/Nischarin was proposed several years ago as the functional entity for the I1 medullary receptors (I1Rs) targeted, together with α2-adrenoceptors, by the centrally acting antihypertensive drugs, such as clonidine. The objective of this study was to test this assumption using a pyrroline analog of clonidine, LNP599, which, unlike clonidine and related compounds, displays high selectivity toward I1Rs. Cardiovascular effects of LNP599 (3 mg/kg intravenous) were evaluated in anesthetized, artificially ventilated nischarin mutant rats expressing a truncated form of nischarin lacking the putative imidazoline binding site. LNP599 induced a rapid and pronounced fall in arterial blood pressure in wild-type animals (−42.7% ± 11.0% after 15 minutes), associated with a ≈30% heart rate reduction. Similar effects were obtained in homozygous and heterozygous nischarin mutant rats. The observation that the hypotensive response to I1R activation is not affected by the absence of the putative imidazoline binding site on nischarin strongly suggests that nischarin cannot be regarded as the functional I1R. Carbohydrate regulation was improved in nischarin mutant rats, further supporting the conclusion that nischarin and I1R are 2 distinct molecular entities.
- 13 March 2021
- Published by Springer Nature
- p. 153-163
5-HT2B Receptor, the Heart and Blood Vessels
- Open Access
High levels of frataxin overexpression leads to mitochondrial and cardiac toxicity in mouse models
Friedreich ataxia (FA) is currently an incurable inherited mitochondrial disease caused by reduced levels of frataxin (FXN). Cardiac dysfunction is the main cause of premature death in FA. AAV-mediated gene therapy constitutes a promising approach for FA, as demonstrated in cardiac and neurological mouse models. While the minimal therapeutic level of FXN protein to be restored and biodistribution have recently been defined for the heart, it is unclear if FXN overexpression could be harmful. Indeed, depending on the vector delivery route and dose administrated, the resulting FXN protein level could reach very high levels in the heart, cerebellum, or in off-target organs such as the liver. The present study demonstrates safety of FXN cardiac overexpression up to 9-fold the normal endogenous level, but significant toxicity to the mitochondria and heart above 20-fold. We show gradual severity with increasing FXN overexpression, ranging from subclinical cardiotoxicity to left ventricle dysfunction. This appears to be driven by impairment of mitochondria respiratory chain, ultrastructure and homeostasis, which lead to myofilaments alteration, cell death and fibrosis. Overall, this study underlines the need, during the development of gene therapy approaches, to consider appropriately vector potency, long term safety and biomarkers to monitor such events.
Open AccessHigh levels of frataxin overexpression leads to mitochondrial and cardiac toxicity in mouse models
Friedreich ataxia (FA) is currently an incurable inherited mitochondrial disease caused by reduced levels of frataxin (FXN). Cardiac dysfunction is the main cause of premature death in FA. AAV-mediated gene therapy constitutes a promising approach for FA, as demonstrated in cardiac and neurological mouse models. While the minimal therapeutic level of FXN protein to be restored and biodistribution have recently been defined for the heart, it is unclear if FXN overexpression could be harmful. Indeed, depending on the vector delivery route and dose administrated, the resulting FXN protein level could reach very high levels in the heart, cerebellum, or in off-target organs such as the liver. The present study demonstrates safety of FXN cardiac overexpression up to 9-fold the normal endogenous level, but significant toxicity to the mitochondria and heart above 20-fold. We show gradual severity with increasing FXN overexpression, ranging from subclinical cardiotoxicity to left ventricle dysfunction. This appears to be driven by impairment of mitochondria respiratory chain, ultrastructure and homeostasis, which lead to myofilaments alteration, cell death and fibrosis. Overall, this study underlines the need, during the development of gene therapy approaches, to consider appropriately vector potency, long term safety and biomarkers to monitor such events.
- 1 February 2019
- Published by Elsevier in Pharmacological Research
- Vol. 140, 33-42
Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?
- 1 February 2019
- Published by Elsevier in Pharmacological Research
- Vol. 140, 33-42
Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?